Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity.

Mohamad SB, Nagasawa H, Sasaki H, Uto Y, Nakagawa Y, Kawashima K, Hori H.

Anticancer Res. 2003 Nov-Dec;23(6a):4451-7.

PMID:
14666733
2.
3.

Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein.

Nagasawa H, Sasaki H, Uto Y, Kubo S, Hori H.

Anticancer Res. 2004 Sep-Oct;24(5C):3361-6.

4.

Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice.

Koga Y, Naraparaju VR, Yamamoto N.

Proc Soc Exp Biol Med. 1999 Jan;220(1):20-6.

PMID:
9893164
6.

Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.

Mohamad SB, Nagasawa H, Uto Y, Hori H.

Comp Biochem Physiol A Mol Integr Physiol. 2002 May;132(1):1-8.

PMID:
12062184
8.

Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.

Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y.

Cancer Immunol Immunother. 2008 Jul;57(7):1007-16. Retraction in: Cancer Immunol Immunother. 2014 Dec;63(12):1349.

9.

Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.

Nagasawa H, Uto Y, Sasaki H, Okamura N, Murakami A, Kubo S, Kirk KL, Hori H.

Anticancer Res. 2005 Nov-Dec;25(6A):3689-95. Review.

11.
12.

Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity.

Kuchiike D, Uto Y, Mukai H, Ishiyama N, Abe C, Tanaka D, Kawai T, Kubo K, Mette M, Inui T, Endo Y, Hori H.

Anticancer Res. 2013 Jul;33(7):2881-5.

PMID:
23780974
13.

Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis.

Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N.

J Natl Cancer Inst. 2002 Sep 4;94(17):1311-9.

PMID:
12208896
14.

A novel assay system for macrophage-activating factor activity using a human U937 cell line.

Ishikawa M, Inoue T, Inui T, Kuchiike D, Kubo K, Uto Y, Nishikata T.

Anticancer Res. 2014 Aug;34(8):4577-81.

PMID:
25075102
15.

Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.

Uto Y, Yamamoto S, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Nakata E, Hori H.

Anticancer Res. 2011 Jul;31(7):2489-92.

PMID:
21873164
16.

Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay.

Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M.

Cancer Immunol Immunother. 2011 Apr;60(4):479-85. doi: 10.1007/s00262-010-0953-7. Epub 2010 Dec 14.

PMID:
21170647
17.
18.

Oleic Acid, deglycosylated vitamin D-binding protein, nitric oxide: a molecular triad made lethal to cancer.

Ruggiero M, Ward E, Smith R, Branca JJ, Noakes D, Morucci G, Taubmann M, Thyer L, Pacini S.

Anticancer Res. 2014 Jul;34(7):3569-78.

PMID:
24982371
19.

Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.

Yamamoto N, Naraparaju VR, Asbell SO.

Cancer Res. 1996 Jun 15;56(12):2827-31.

20.

Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin.

Morucci G, Branca JJ, Gulisano M, Ruggiero M, Paternostro F, Pacini A, Di Cesare Mannelli L, Pacini S.

Anticancer Drugs. 2015 Feb;26(2):197-209. doi: 10.1097/CAD.0000000000000177.

PMID:
25304987

Supplemental Content

Support Center